Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa scheda tecnica

besponsa scheda tecnica

Перейти к контенту

Главное меню:

Разное
besponsa scheda tecnica
Besponsa: Scheda Tecnica e Prescrivibilità - schedefarmaci.it, Besponsa: Scheda Tecnica e Prescrivibilità | Torrinomedica, Besponsa | European Medicines Agency, Besponsa (inotuzumab ozogamicin) – Riassunto delle , BESPONSA 1 mg powder for concentrate for solution for , NDC 0008-0100 Besponsa Inotuzumab Ozogamicin, Welcome to BESPONSA® | BESPONSA®, ALLEGATO I RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO, ALLEGATO I RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO.
For patient-reported outcomes, most functioning and symptom scores were in favour of BESPONSA compared to Investigator's choice of chemotherapy. Patient-reported outcomes measured using the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), were significantly better for BESPONSA by estimated mean postbaseline scores (BESPONSA and Investigator's choice of chemotherapy, respectively) for role functioning (64.7 versus 53.4, improvement grade small), physical functioning (75.0 versus 68.1, improvement grade small), social functioning (68.1 versus 59.8, improvement grade medium), and appetite loss (17.6 versus 26.3, improvement grade small) compared to Investigator's choice of chemotherapy. There was a trend in favour of BESPONSA, improvement grade small, for estimated mean postbaseline scores (BESPONSA and Investigator's choice, respectively) in global health status/Quality of Life (QoL) (62.1 versus 57.8), cognitive functioning (85.3 versus 82.5), dyspnoea (14.7 versus 19.4), diarrhoea (5.9 versus 8.9), fatigue (35.0 versus 39.4). There was a trend in favour of BESPONSA for estimated mean postbaseline scores from the EuroQoL 5 Dimension (EQ-5D) questionnaire, (BESPONSA and Investigator's choice of chemotherapy, respectively) for the EQ-5D index (0.80 versus 0.76, minimally important difference for cancer = 0.06).. Besponsa Riassunto delle Caratteristiche del Prodotto Besponsa: ultimo aggiornamento pagina: 20/10/2018 (Fonte: A.I.FA.) Indice della scheda Denominazione del medicinale Composizione qualitativa e quantitativa Forma farmaceutica Indicazioni terapeutiche Posologia e modo di. Besponsa - Inotuzumab Ozogamicin - BESPONSA è indicato in monoterapia per il trattamento di pazienti adulti con leucemia linfoblastica acuta (LLA) da precursori delle cellule B CD22-positivi, .
Besponsa is a cancer medicine used to treat a type of blood cancer which affects B cells (a type of white blood cells) called B-cell precursor acute lymphoblastic leukaemia (ALL).. Besponsa – Riassunto delle caratteristiche del prodotto - inotuzumab ozogamicin - L01XC - Pfizer Limited. There was a trend in favour of BESPONSA for estimated mean postbaseline scores from the EuroQoL 5 Dimension (EQ-5D) questionnaire, (BESPONSA and Investigator's choice of chemotherapy, respectively) for the EQ-5D index (0.80 versus 0.76, minimally important difference for cancer = 0.06).. Besponsa with NDC 0008-0100 is a a human prescription drug product labeled by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.. The generic name of Besponsa is inotuzumab ozogamicin.. BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age.. BESPONSA deve essere somministrato in cicli da 3 a 4 settimane. Per i pazienti che procedono altrapianto di cellule staminali ematopoietiche (HSCT), la durata raccomandata del trattamentoè di 2cicli..
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню